News|Articles|November 20, 2026

Systematic Review Finds Higher-Valency Pneumococcal Vaccines Offer Strong Economic Value for US Adults

Listen
0:00 / 0:00

Key Takeaways

  • Forty US economic evaluations (mostly Markov-based cost-effectiveness analyses) were moderate-to-high quality by CHEERS 2022, supporting robust conclusions despite heterogeneity precluding meta-analysis.
  • Base-case ICERs were commonly below $50,000–$150,000/QALY, with the strongest value in older adults and those with chronic comorbidities driving high pneumococcal burden.
SHOW MORE

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.

Pneumococcal vaccination represents a high-value public health investment for US adults, particularly with higher-valency vaccines such as the 20-valent pneumococcal conjugate vaccine (PCV20) and 21-valent PCV (PCV21), according to a systematic review conducted by researchers from the University of Florida College of Pharmacy and presented at IDWeek in Washington, DC. The investigators also found that low and uneven vaccine uptake continues to limit the health and economic benefits of vaccination.1

Despite the availability of PCVs, pneumococcal disease continues to cause substantial morbidity, mortality, and economic burden among US adults. Pneumococcal pneumonia accounts for approximately 12% to 13% of hospitalized pneumonia cases and an estimated 225,000 adult hospitalizations annually. In October 2024, the CDC’s Advisory Committee on Immunization Practices (ACIP) expanded its recommendation to a single PCV dose for all PCV-naïve adults aged 50 years and older.1,2

Review Included 40 US Economic Studies

The investigators followed PRISMA 2020 guidelines and registered the review on PROSPERO (CRD420251145014). They searched PubMed, MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library for cost-effectiveness, cost-utility, cost-benefit, and cost-of-illness studies of pneumococcal disease or vaccination in US adults aged 18 years and older, published between January 2010 and February 2025. Two reviewers independently extracted data, and methodological quality was assessed using the CHEERS 2022 checklist. Because the data were heterogeneous, results were described narratively.1

Of 5229 records screened, 40 studies met inclusion criteria. Most were cost-effectiveness analyses (n = 28), and 22 of those used Markov models. Overall study quality was moderate to high, with approximately 40% of studies rated high quality and 60% rated moderate quality. None were rated as low quality.1

Higher-Valency Vaccines Were Most Cost-Effective

Among the 28 cost-effectiveness analyses, 23 reported base-case incremental cost-effectiveness ratios below commonly applied US willingness-to-pay thresholds of $50,000 to $150,000 per quality-adjusted life-year (QALY). Vaccination was generally cost-effective, especially in older adults and those with chronic conditions. PCV20 and PCV21 strategies consistently outperformed earlier strategies, including PCV13, PCV15, and the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Sixteen studies reported improved cost-effectiveness and reduced population-level burden as vaccine uptake increased.1

Earlier modeling supports the advantage of single-dose strategies. In a Markov analysis of adults aged 65 years, PCV20 was substantially more economically favorable than PCV15, followed by PPSV23 in both Black and non-Black cohorts. When the simpler 1-vaccine PCV20 strategy was modeled to increase uptake by about 10 percentage points, PCV15/PPSV23 cost more than $5 million per QALY gained.3

Uptake Remains Low and Uneven

The review found that adults with chronic diseases carry a large share of the disease burden, yet their vaccine uptake was only 20% to 40%, compared with 60% to 70% among older adults. Coverage among Black adults was approximately 8% to 15% lower than among White adults. Of the 40 studies, 25 reported adult vaccine coverage rates, and targeted implementation programs increased coverage by approximately 10 to 20 percentage points.1

National data show similar gaps. In 2024, only 24.1% of adults aged 19 to 64 years at increased risk had received at least 1 pneumococcal vaccine dose. Among adults aged 65 years and older, coverage was approximately 64.7% overall, 68.3% among White adults, 54.6% among Black adults, and 48.6% among Hispanic adults. Coverage in older adults has declined since 2018 and remains below prepandemic levels.4

In addition, invasive pneumococcal disease rates caused by serotypes not covered by PCV13 are higher among Black and American Indian/Alaska Native adults than in the general population, and IPD rates among Black adults peak at ages 55 to 59 years. These disparities informed ACIP’s decision to lower the age-based recommendation to 50 years.2

Implications for Pharmacists

The investigators concluded that improving uptake through targeted implementation programs is critical to maximizing the health impact of vaccination and reducing equity gaps. Pharmacists are well positioned to identify adults with chronic conditions who have not been vaccinated, recommend single-dose PCV20 or PCV21 regimens that simplify series completion, and reach communities with lower coverage.1,3

The authors added that the predominance of moderate- to high-quality studies strengthens confidence in the conclusions, but reporting transparency in economic evaluations should continue to improve.1

REFERENCES
1. Kallala K, Baerga A, Barreto F, Shifa NN, Vadlamudi NK. Economic impact of pneumococcal disease in U.S. adults: a systematic review. Poster presented at: IDWeek; October 21-24, 2026. Washington, DC.
2. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1
3. Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of newly recommended pneumococcal vaccination strategies in older underserved minority adults in the USA. Infect Dis Ther. 2022;11(4):1683-1693. doi:10.1007/s40121-022-00669-x
4. Vaccination coverage among adults in the United States, National Health Interview Survey, 2024. News release. CDC. Updated June 1, 2026. Accessed November 19, 2026. https://www.cdc.gov/adultvaxview/publications-resources/vaccination-coverage-adults-2024.html

Related to this article